£2 Ask....Why I bought Avacta 2 months ago & still buying today26 May 2020 11:25
Summary reasons and detail below:
SUMMARY here:
- Highly accurate rapid Antigen testing is expected. RAPID. AFFORDABLE. EASE TO USE. MASS PRODUCED. HOME TEST KIT.
- Other Testing / Therapy / Vaccine collaborations
- US / EU Approvals
- Commercialisation Deals
- Dual Listings
DETAIL here:
Might be useful to consider what we know and what we do not yet know, specific to Antigen Testing work:
What WE KNOW:
We are developing a world class, globally produced, affordable, rapid Antigen Test
We have 2 key partners so far for Covid19 Antigen testing
We are actively seeking commercialisation deals
We are seeking further collaboration partners
We will be going for EU and US approvals
What WE DO NOT KNOW
How accurate the Antigen Testing will be, though it promises to be highly accurate but we do not have the % yet
The granting of EU/ US approvals
The details of the commercialisation deal / The value of the contracts
Which other collaboration partners we will sign up with
Dual listing possibilities
*****Will the collaborations involve a Vaccine partner…..**********
The first 3 on the “what we do not know” combined could take us into the £6/7 per share territory.
The last dual listing could further help increase that value.
As for collaborations that we haven’t even thought about and by this I mean a “left centre” success that could happen but is not on the investor radar then I do not think a double digit pounds per share price is unreasonable. Look right now, no one really knows how far this share could go. But what is clear is that no one is able to put up a strong argument that says Avacta cannot leave our current SP behind when there is so much left on the table to go after in terms of the multi billion market.
GL all